Kbc Group Nv Xencor Inc Transaction History

Kbc Group Nv

$36.3 Billion
Q4 2024

A detailed history of Kbc Group Nv transactions in Xencor Inc stock. As of the latest transaction made, Kbc Group Nv holds 3,936 shares of XNCR stock, worth $81,357. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,936

Previous 3,123 26.03%

Holding current value

$81,357

Previous $63,000 42.86%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 22, 2025	BUY	$19.43 - $26.84 $15,796 - $21,820	813 Added 26.03%	3,936 $90,000
Q3 2024 Nov 06, 2024	BUY	$15.7 - $21.65 $19,044 - $26,261	1,213 Added 63.51%	3,123 $63,000
Q4 2023 Feb 13, 2024	SELL	$16.53 - $21.42 $39,457 - $51,129	-2,387 Reduced 55.55%	1,910 $41,000
Q3 2023 Feb 15, 2024	SELL	$20.08 - $25.39 $47,930 - $60,605	-2,387 Reduced 55.55%	1,910 $38,000
Q2 2023 Feb 15, 2024	SELL	$24.77 - $29.9 $19,147 - $23,112	-773 Reduced 15.25%	4,297 $107,000
Q2 2023 Jul 28, 2023	SELL	$24.77 - $29.9 $19,147 - $23,112	-773 Reduced 15.25%	4,297 $107,000
Q3 2022 Feb 15, 2024	BUY	$24.62 - $32.44 $77,799 - $102,510	3,160 Added 165.45%	5,070 $132,000
Q2 2022 Feb 14, 2024	BUY	$19.74 - $29.01 $41,572 - $61,095	2,106 Added 71.05%	5,070 $139,000
Q2 2022 Jul 26, 2022	BUY	$19.74 - $29.01 $41,572 - $61,095	2,106 Added 71.05%	5,070 $139,000
Q4 2021 Feb 14, 2024	BUY	$33.67 - $43.44 $35,488 - $45,785	1,054 Added 55.18%	2,964 $119,000
Q3 2021 Nov 10, 2021	BUY	$30.65 - $35.68 $90,846 - $105,755	2,964 New	2,964 $97,000

Others Institutions Holding XNCR

# of Institutions

216

Shares Held

71.5M

Call Options Held

2.5K

Put Options Held

7.9K

View Full List

About Xencor Inc

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.23B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

More about XNCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.

Account